Target intelligence / Profile preview

MLLT10 histone lysine methyltransferase DOT1L cofactor (MLLT10)

Target
MLLT10
Molecular classification
Transcription factor, Chromatin modifier/cofactor, Histone modification (via DOT1L association), DNA-binding protein
01

Overview

MLLT10 histone lysine methyltransferase DOT1L cofactor (MLLT10/AF10) is a 109-kDa chromatin-associated protein encoded on chromosome 10p12, belonging to a conserved family including AF17 and BR140. It contains PHD fingers, an extended PHD/LAP domain, AT-hook motif, nuclear localization signal, and a glutamine-rich C-terminal region. AF10 forms oncogenic fusion proteins through chromosomal translocations in leukemia, most prominently with CALM or MLL/KMT2A, generating aberrant transcription factors that drive malignant transformation by mislocalizing DOT1L. The resulting gene fusions dysregulate HOXA cluster genes and disrupt normal hematopoietic cell differentiation. AF10's normal biological functions include chromatin binding, transcriptional regulation, and interaction with DOT1L to mediate H3K79 methylation. Aberrant function, loss of key domains, or fusion with other proteins underlies its role in leukemia pathogenesis and provides a rationale for targeting DOT1L in therapy.

Other names
Protein AF-10AF10ALL1-fused gene from chromosome 10 proteinmyeloid/lymphoid or mixed-lineage leukemia; translocated to, 10type I AF10 proteintype III AF10 proteintype IV AF10 protein
02

Mechanism of action

Inhibition of DOT1L: prevents abnormal H3K79 methylation and subsequent dysregulation of HOXA cluster gene expression that drives leukemogenesis in MLLT10 fusion leukemias

03

Biological functions

Transcriptional regulationChromatin organizationHematopoietic cell differentiationDOT1L-mediated H3K79 methylation of histones
04

Disease associations

Cancer (especially acute myeloid leukemia, acute lymphoblastic leukemia, pediatric leukemias)Disorders associated with chromosomal translocations
05

Safety considerations

Drug target-related: Limited by off-target effects and the challenges of targeting epigenetic regulators like DOT1LDisease-related: MLLT10/fusion-driven leukemias have poor prognosis and are often chemoresistant, complicating treatment
06

Interacting drugs

Pinometostat (EPZ-5676; a DOT1L inhibitor, targets leukemia driven by MLL fusion proteins including those involving AF10/MLLT10)
07

Biomarkers

CALM-AF10 fusion transcript (used to identify patients with specific subtypes of leukemia)Upregulation of HOXA cluster genes in leukemia cells

Beyond the preview

Go deeper on MLLT10 histone lysine methyltransferase DOT1L cofactor (MLLT10).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on MLLT10 histone lysine methyltransferase DOT1L cofactor (MLLT10).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call